Chabiotech Co., Ltd.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.chabio.com
Phase 1 Clinical Trial of CordSTEM-ST
Phase 1
Recruiting
- Conditions
- Premature Ovarian Insufficiency
- Interventions
- Biological: umbilical cord-derived mesenchymal stem cell
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- CHABiotech CO., Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT06578039
- Locations
- π°π·
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- Biological: CBT101 cells, every 4 weeksBiological: CBT101 cells, every 2 weeks
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- CHABiotech CO., Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT04557306
- Locations
- π°π·
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain
Phase 1
Completed
- Conditions
- Chronic Low-back PainDisc Degeneration
- Interventions
- Biological: PlaceboBiological: CordSTEM-DD (2.1 x 10^7 cells)Biological: CordSTEM-DD (0.7 x 10^7 cells)
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- CHABiotech CO., Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT04530071
- Locations
- π°π·
CHA Bundand Medical Center, Seongnam-si, Korea, Republic of
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
Phase 1
Active, not recruiting
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: PlaceboBiological: CB-AC-02
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- CHABiotech CO., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT02899091
- Locations
- π°π·
Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction
Phase 1
Completed
- Conditions
- Cerebral Infarction
- Interventions
- Biological: Cordstem-STBiological: Placebo
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- CHABiotech CO., Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT02378974
- Locations
- π°π·
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD
Phase 1
Terminated
- Conditions
- Dry Age Related Macular Degeneration
- Interventions
- Biological: MA09-hRPE
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- CHABiotech CO., Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT01674829
- Locations
- π°π·
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)
Phase 1
Completed
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- Biological: MA09-hRPE
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- CHABiotech CO., Ltd
- Target Recruit Count
- 3
- Registration Number
- NCT01625559
- Locations
- π°π·
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath